NAS
TVTX icon

Nykredit A/S’s Travere Therapeutics TVTX Stock Holding History

Nykredit A/S’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237K Buy
+4,173
New +$185K ﹤0.01% 964

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Nykredit A/S's TVTX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 4,173 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #964 among its holdings.

218 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Nykredit A/S held 4,173 shares of Travere Therapeutics worth $237K as of Q2 2026.
  • Travere Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #964 holding.
  • 218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.